Xenon News and Activities
Presence
Xenon develops medicines for neurological and other serious diseases. Its main services include drug discovery and clinical-stage therapies for patients, healthcare providers, and pharmaceutical partners.
Xenon products and services overview:
- Drug discovery
- Clinical development
- Neurology treatments
- Epilepsy therapies
- Pain treatments
- Research partnerships
Revenue: ~$8 million
Employees: 350
Headquarters: Burnaby, Canada
Xenon is one of the...
Xenon is a company listed under the stock ticker XENE (CA).
Acquisition, funding and merger involving Xenon.
- Xenon has just announced a $748 Million fundraising (posted on April 17 2026).
Executives
View the org chart displaying its 25 main executives
Most searched biographies at Xenon
- Ian Mortimer, President, Chief Executive Officer and Director
- Justin Gover, Director
- Steven Gannon, Director
Popular executive movements at Xenon
- Tucker Kelly has joined the company as Chief Financial Officer (posted on October 16 2025).
Create your alert
to follow the executive moves at Xenon.
Pharmaceuticals
Xenon has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
- Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Xenon
- Xenon Reports Q1 2026 Financial Results and Provides Business Update | Xenon Pharmaceuticals Inc.
- Xenon to Report Q1 2026 Financial Results on May 7, 2026 | Xenon Pharmaceuticals Inc.
- Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Xenon Pharmaceuticals Inc.
- Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting | Xenon Pharmaceuticals Inc.
- Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences | Xenon Pharmaceuticals Inc.
- Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update | Xenon Pharmaceuticals Inc.
- Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update | Xenon Pharmaceuticals Inc.
- Xenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit | Xenon Pharmaceuticals Inc.
- Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology | Xenon Pharmaceuticals Inc.
- Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit | Xenon Pharmaceuticals Inc.
- View more press releases Close
Social media about Xenon
- Xenon on Wikipedia, Google News & Yahoo Finance
- Xenon on LinkedIn, X (Twitter) & YouTube
